Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has submitted its FY2023 Audit Report, receiving an ‘Unqualified’ opinion from Samil PricewaterhouseCoopers for its consolidated revenue of KRW 3.69T and operating profit of KRW 1.11T.
📊 [Key Disclosure Details & Financial Figures]
- External Auditor: Samil PricewaterhouseCoopers
- Audit Report Receipt Date: 2023-02-28 (As stated in the original disclosure)
- Audit Opinion & Major Items (Both Consolidated and Separate):
- Audit Opinion: Unqualified
- Issues Regarding Going Concern Uncertainty: Not Applicable
- Adverse Opinion on Internal Accounting Control System: Not Applicable
- Embezzlement or Breach of Fiduciary Duty Mentioned in Audit Report: No
- FY2023 Consolidated Financial & Earnings Figures:
- Total Assets: KRW 16,046,197,209,196
- Total Liabilities: KRW 6,215,704,796,851
- Total Equity: KRW 9,830,492,412,345 (Capital Stock: KRW 177,935,000,000)
- Revenue: KRW 3,694,588,767,068 (Prior FY: KRW 3,001,295,197,683)
- Operating Profit: KRW 1,113,680,009,715 (Prior FY: KRW 983,627,394,377)
- Profit Before Income Tax Expenses: KRW 1,119,986,931,201
- Net Profit: KRW 857,691,298,384 (Same as Net Profit Attributable to Owners of Parent)
- Number of Consolidated Subsidiaries: 14 (Major Subsidiaries: 1)
- FY2023 Separate Financial & Earnings Figures:
- Total Assets: KRW 11,831,260,604,556
- Total Liabilities: KRW 3,592,626,821,824
- Total Equity: KRW 8,238,633,782,732 (Capital Stock: KRW 177,935,000,000)
- Revenue: KRW 2,938,755,680,729 (Prior FY: KRW 2,437,286,111,838)
- Operating Profit: KRW 1,204,187,993,041 (Prior FY: KRW 968,050,593,669)
- Profit Before Income Tax Expenses: KRW 1,224,183,412,500
- Net Profit: KRW 945,920,325,918
- Other Remarks: Financial statements are subject to potential changes during the approval process at the Annual General Meeting of Shareholders.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Shareholder Approval and Final Confirmation of Financial Figures
This disclosure reports that Samsung Biologics has received an ‘Unqualified’ audit opinion from Samil PricewaterhouseCoopers and disclosed its audited financial statements for FY2023. Tracking whether these audited figures pass through the upcoming Annual General Meeting of Shareholders without modifications is essential to confirm the finality and reliability of the reported financial performance. Investors can verify the final approval status through the subsequent Results of Annual General Meeting disclosure and the upcoming Annual Report.
📢 Disclaimer and Source Notice
Source: This content was structured and newly generated based on official submission data from the Financial Supervisory Service DART system.
Investment Risk Warning: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial liabilities rest entirely with the individual investor.
Contact: For regulatory compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.
